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Background: Asthma is often poorly controlled and guidelines are often inadequately followed in medical practice.
In particular, the prescription of non-asthma-specific drugs can affect the quality of care. The goal of this study was
to measure the frequency of the prescription of antibiotics and anxiolytics/hypnotics to asthmatic patients and to
look for associations between sex or age and the prescription of these drugs.
Methods: A cross-sectional study was conducted using computerised medical records from French and Italian
general practitioners’ networks. Patients were selected according to criteria adapted from the HEDIS (Healthcare
Effectiveness Data and Information Set) criteria. The outcome measure was the number of antibiotics or
anxiolytics/hypnotics prescriptions per patient in 1 year. Parallel multivariate models were developed.
Results: The final sample included 3,093 French patients (mean age 27.6 years, 49.7% women) and 3,872 Italian
patients (mean age 29.1 years, 48.7% women). In the univariate analysis, the French patients were prescribed fewer
antibiotics than the Italian patients (37.1% vs. 42.2%, p < 0.00001) but more anxiolytics/hypnotics (17.8% vs. 6.9%,
p < 0.0001). In the multivariate models, the female patients were more likely to receive antibiotics (odds ratio:
1.5 [1.3–1.7]) and anxiolytics/hypnotics (odds ratio: 1.8 [1.5–2.1]).
Conclusions: The prescription of antibiotics and anxiolytics/hypnotics to asthmatic patients is frequent, especially in
women. Asthma guidelines should address this issue by referring to other guidelines covering the prescription of
non-asthma-specific drugs, and alternative non-pharmacological interventions should be considered.
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Despite international guidelines [1], the proportion of
patients with uncontrolled asthma remains high, inde-
pendent of disease severity [2,3]. Among asthma-specific
drugs, inhaled corticosteroids are often underused, and
rescue medication is frequently overused [4,5]. Studies
investigating insurance claims data have suggested that
non-asthma-specific drugs such as antibiotics [6] or
anxiolytics/hypnotics are widely prescribed to asthmatic* Correspondence: david.darmon@unice.fr
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unless otherwise stated.patients [7] and to the general population [8,9]. The pre-
scription of first-line antibiotics in primary care in-
creases the population carriage of resistant organisms in
the community and the use of second-line antibiotics
[10]. Prescription of anxiolytics and hypnotics in primary
care leads to addiction and other side effects such as
daytime fatigue, ataxia, falls, and road traffic incidents
[11]. Importantly, the actual prescribing of these drugs
to asthmatic patients has been poorly studied in primary
care practice. Direct comparisons of patients receiving
and not receiving these prescriptions are lacking. This
study aimed to measure the frequency of the prescrip-
tion of antibiotics and anxiolytics/hypnotics to asthmatic
patients and to look for any association between sex orl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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compared the prescription profiles in general practice
in two European countries with different healthcare
systems for which comparable databases are available,
namely France and Italy.
Methods
Data sources
We conducted a cross-sectional study using data from
computerised French and Italian primary care databases.
These two clinical databases, operated by Cegedim
Strategic Data, collect consultation data from a network
of 1200 general practitioners (GPs) (3% of French GPs)
[12] distributed across France and a network of 700 GPs
(1.3% of Italian GPs) [13] across Italy. Participating GPs
continuously and voluntarily provide anonymised and
coded patient data to a centralised database using an elec-
tronic health record system that is common within each
country. In both countries, participating GPs are selected
to be representative of the French and Italian populations,
respectively, according to three main criteria: geographical
area, age, and sex. Activity and prescription habits of the
panels have also been compared with national data and
shown to be representative [14-16]. This procedure has
been approved in France by the National Data Protection
Authority (ethics committee) since 2002 (reference
number: 770334) and in Italy by the National Data Pro-
tection Authority since 2004 (no reference number).
The data include patient demographic characteristics
and the diagnoses and prescriptions related to each
consultation. The quality of these databases has been
checked regularly, and they have been used frequently
for pharmacoepidemiological studies [17,18].
Data extraction
The following variables were extracted from the data-
bases: patient age and sex, number of visits to the GP
and prescribed drugs, classified according to the Ana-
tomical Therapeutic Chemical classification (ATC) [19].
Asthma drug categories belong to the ATC class R03
(Drugs for obstructive airway diseases) and include
short-acting inhaled beta-agonists, long-acting inhaled
beta-agonists (R03AC), oral beta-agonists (R03CC), theo-
phylline (R03DA04), cromoglicic acid (R03BC), inhaled
corticosteroids (R03BA), anticholinergics and leukotriene
receptor antagonists (alone or in combination) (R03DC).
We also extracted data on the use of oral corticosteroids
(HA02AB). The following antibiotics were used for respira-
tory tract infections: tetracyclines (J01A), amphenicols
(J01B), macrolides (J01F), beta-lactams (J01C), sulpho-
namides (J01E), cephalosporins (J01D), aminoglycosides
(J01G) and quinolones (J01M). We also extracted data
on all anxiolytics (N05B), hypnotics/sedatives (N05C),
nasal preparations (R01) and antidepressants (N06A).Inclusion criteria
From a pre-selected group of patients with at least one
R03 prescription in 2007, we included in the analyses all
patients between the ages of 13 and 40 years on the first
of January 2008 who consulted during the year 2007 or
2008 and who fulfilled the asthma criteria derived from
Health Employer Data and Information Set criteria
(HEDIS criteria) [20]. These criteria are based on pre-
scriptions and are more accurate in retrieving data on
asthmatic patients than criteria based on diagnostic
label [21]. These criteria consisted of the prescription
of four or more units of any ATC R03 class drug (alone
or in combination), or four or more outpatient visits with
a diagnosis of asthma and two or more drug prescriptions
used in the treatment of asthma, within a year. Patients
with any prescription of tiotropium bromide (R03BB04) in
2007 or 2008 were excluded, as well as those over 40 years
old, to limit the risk of confusion with chronic obstructive
pulmonary disease diagnosis.
Statistical analyses
We used the issue of at least one prescription (one drug
box versus none) as the outcome variable. First, the pro-
portion of patients who received a prescription of at
least one box of antibiotics or anxiolytics/hypnotics in
2008 was estimated for France and Italy. Then, these
patients were compared with the other patients using a
chi-square test for univariate analyses and a logistic
regression model for multivariate analyses. These statis-
tical analyses were performed using SAS 9.3 software
(SAS Institute Inc., Cary, NC, USA). The selected level
of significance was 0.05. In the univariate analyses, we
estimated the prescription frequencies of at least one
antibiotic and one hypnotic/sedative or anxiolytic in 2008.
Using chi-square tests, we compared these frequencies
between France and Italy and assessed the influence of
patient age and sex, as well as the influence of the pre-
scription of nasal preparations and antidepressants, as in-
dicators of conditions frequently associated with asthma,
such as rhinitis and depression.
Multivariate analyses were then conducted, based on lo-
gistic regression models after combining the French and
Italian samples. We estimated odds ratios adjusted for
asthma control criteria and severity (aOR), i.e. more than
six prescriptions of short-acting inhaled beta-agonists
(R03AC excluding R03AC12, R03AC13, R03AC14 and
R03AC18) in 2008; the prescription of at least one in-
haled corticosteroid (R03BA) in 2008, one inhaled asthma
controller (R03AC12, R03AC13, R03AC14, R03AC18,
R03AK06, R03AK07, R03BA, R03BC, R03DC, R03DA,
R03DB or R03DX05), one oral corticosteroid (HA02AB) or
the number of asthma drug units (R03; 1–7, 8–14, ≥15);
and more than 12 visits to the GP with a prescription of an
ATC R03 class medication in 2008.
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The final sample included 3,093 French patients (mean
age 27.6 years, 49.7% women) and 3,878 Italian patients
(mean age 29.1 years, 48.7% women) (Figure 1). From
our database, we estimated baseline proportions of
29.1% in France and 36.2% in Italy for non-asthmatic pa-
tients aged from 13 to 40 years in 2008 who were pre-
scribed at least one box of antibiotics. For anxiolytics/
hypnotics, the respective estimates were 9.5% in France
and 3.2% in Italy. After adjustment for age, the prescrip-
tion of antibiotics and anxiolytics/hypnotics was higher
in asthmatic patients, as compared with non-asthmatic
patients both in France (OR = 1.4, 95% CI [1.3–1.5] and
OR = 2.1, 95% CI [1.9–2.3]) and in Italy (OR = 1.3, 95%
CI [1.2–1.4] and OR = 2.2, 95% CI [1.9–2.5]) (Table 1).
Prescription of antibiotics
The proportion of asthmatic patients having at least one
prescription of antibiotics in 2008 was higher in Italy
than in France (42.1% vs. 37.1%, p < 0.0001). These pre-
scriptions were more frequent in older patients in Italy
and in female patients in both France and Italy (Table 2).
Prescription of anxiolytics/hypnotics
The proportion of asthmatic patients with at least one
prescription for anxiolytics or hypnotics in 2008 wasFigure 1 Sample selection in France and Italy.more frequent in France than in Italy (17.8% vs. 6.9%,
p < 0.0001). The prescription of anxiolytics or hypnotics
was more frequent in older and female patients in both
countries (Table 3).
In the multivariate analyses (Table 4), the prescription
of antibiotics was less frequent in France than in Italy
(aOR = 0.8, 95% CI [0.7–0.9]) and more frequent in female
than in male patients (aOR = 1.5, 95% CI [1.3–1.6]). The
prescription of antibiotics was also associated with the
prescription of nasal preparations (aOR = 2.0, 95% CI
[1.7–2.2]). The prescription of anxiolytics or hypnotics
was more frequent in France than in Italy (aOR = 5.0,
95% CI [3.4–5.3]), in female patients (aOR = 1.8, 95% CI
[1.5–2.1]) and in older patients (aOR = 1.9, 95% CI
[1.3–2.8] between 18 and 30 years and 3.3, 95% CI
[2.3–4.7] between 31 and 40 years). The prescription of
these drugs was associated with the prescription of an-
tidepressants (aOR = 9.6, 95% CI [7.7–11.9]).
Discussion
Main findings
Using the data from two large computerised databases,
we observed that non-asthma-specific drugs are commonly
prescribed to asthmatic patients in France and Italy. In par-
ticular, in 2008, 37.1% of the French patients and 42.1% of
the Italian patients were prescribed antibiotics, and 17.8%
Table 1 Prescription of antibiotics and anxiolytics/hypnotics (at least one prescription in 2008) for asthmatic and
non-asthmatic patients in France and in Italy according to patient age
Asthmatic patient Non-asthmatic patient
Yes No Yes No OR (95% CI)
Antibiotics
France
Patients 1147 (37.1) 1946 (62.9) 190641 (29.1) 465037 (70.1) 1.43 (1.33-1.54)
[13-17] 169 (14.7) 316 (16.2) 24249 (12.7) 69162 (14.9)
[18-29] 433 (37.7) 784 (40.3) 81854 (42.9) 211543 (45.5)
[30-40] 545 (47.5) 846 (43.5) 84538 (44.3) 184332 (39.6)
Italy
Patients 1634 (42.1) 2244 (57.9) 96406 (36.2) 169550 (63.8) 1.28 (1.20-1.37)
[13–17] 180 (11.0) 238 (10.6) 10990 (11.4) 20334 (12.0)
[18–29] 528 (32.3) 839 (37.4) 37915 (39.3) 65213 (38.5)
[30–40] 926 (56.7) 1167 (52.0) 47501 (49.3) 84003 (49.5)
Anxiolytics/Hypnotics
France
Patients 551 (17.8) 2542 (82.2) 62003 (9.5) 593675 (90.5) 2.08 (1.90-2.29)
[13–17] 28 (5.1) 457 (18.0) 3010 (4.9) 90401 (15.2)
[18–29] 185 (33.6) 1032 (40.6) 24513 (39.5) 268884 (45.3)
[30–40] 338 (61.3) 1053 (41.4) 34480 (55.6) 234390 (39.5)
Italy
Patients 267 (6.9) 3611 (93.1) 8454 (3.2) 257502 (96.8) 2.19 (1.93-2.48)
[13–17] 9 (3.4) 409 (11.3) 179 (2.1) 31145 (12.1)
[18–29] 56 (21.0) 1311 (36.3) 2393 (28.3) 100735 (39.1)
[30–40] 202 (75.6) 1891 (52.4) 5882 (69.6) 125622 (48.8)
Data are presented as n (%) and OR denotes odds ratios adjusted on age and presented with their 95% confidence interval.
Table 2 Prescription of antibiotics in France and in Italy (at least one prescription in 2008) according to patient age,
sex, and nasal preparation and antidepressant prescriptions (univariate analyses)
France Italy
Yes No P-value Yes No P-value
Patients 1147 (37.1) 1946 (62.9) 1634 (42.1) 2244 (57.9)
Age (yrs.)
[13–17] 169 (14.7) 316 (16.2) 0.09 180 (11.0) 238 (10.6) <0.01
[18–29] 433 (37.7) 784 (40.3) 528 (32.3) 839 (37.4)
[30–40] 545 (47.5) 846 (43.5) 926 (56.7) 1167 (52.0)
Sex
Female 686 (59.8) 852 (43.8) <0.0001 902 (55.2) 983 (43.9) <0.0001
Male 461 (40.2) 1094 (56.2) 731 (44.8) 1256 (56.1)
Nasal preparations prescription*
No 293 (25.5) 1055 (54.2) <0.001 1428 (87.4) 2007 (89.4) <0.05
Yes 854 (74.5) 891 (45.8) 206 (12.6) 237 (10.6)
Antidepressants prescription*
No 1038 (90.5) 1831 (94.1) <0.001 1503 (92.0) 2112 (94.1) <0.05
Yes 109 (9.5) 115 (5.9) 131 (8.0) 132 (5.9)
Data are presented as n (%). *At least one prescription in 2008.
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Table 3 Prescription of anxiolytics/hypnotics (at least one prescription in 2008) in France and in Italy according to
patient age, sex, and nasal preparation and antidepressant prescriptions (univariate analyses)
France Italy
Yes No P-value Yes No P-value
Patients 551 (17.8) 2542 (82.2) 267 (6.9) 3611 (93.1)
Age (yrs.)
[13–17] 28 (5.1) 457 (18.0) <0.0001 9 (3.4) 409 (11.3) <0.0001
[18–29] 185 (33.6) 1032 (40.6) 56 (21.0) 1311 (36.3)
[30–40] 338 (61.3) 1053 (41.4) 202 (75.6) 1891 (52.4)
Sex
Female 359 (65.15) 1179 (46.4) 186 (69.7) 1699 (47.1)
Male 192 (34.8) 1363 (53.6) <0.0001 81 (30.3) 1906 (52.9) <0.0001
Nasal preparations*
No 222 (40.3) 1126 (44.3) 0.09 237 (88.8) 3198 (88.6) 0.92
Yes 329 (59.7) 1416 (55.7) 30 (11.2) 413 (11.4)
Prescription of antidepressants*
No 401 (72.8) 2468 (97.1) <0.0001 169 (63.3) 3446 (95.4) <0.0001
Yes 150 (27.2) 74 (2.9) 98 (36.7) 165 (4.6)
Data are presented as n (%). *At least one prescription in 2008.
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prescribed anxiolytics or hypnotics. A higher frequency of
prescription was observed for female patients for these two
drug categories in both countries and in older patients for
anxiolytics or hypnotics in France. These results are com-
parable to known rates of prescription for antibiotics, anxi-
olytics and hypnotics in non-asthmatic patients.
Strengths and limitations
A strength of this study is the use of accurate drug pre-
scription data from community-based general practice,
where asthmatic patients are treated most of the time.
Our data come from France and Italy, countries with
poor documentation of primary care performance [22].
Our analyses are based on prescription data, not onTable 4 Prescription of antibiotics and of anxiolytics/hypnotic
country, patient age, sex, and nasal preparation and antidep
and severity criteria (multivariate logistic models)
Model 1 Prescription of a
one antibiotic in 2008 (n
Factors
France (vs. Italy) 0.76 (0.66- 0.87)
Age [18–29] (vs. [13–17]) 0.98 (0.83-1.16)
Age [30–40] (vs. [13–17]) 1.10 (0.93-1.30)
Female (vs. Male) 1.48 (1.34-1.65)
Nasal preparations* 1.99 (1.75-2.27)
Antidepressants* 1.22 (1.00-1.49)
Data are presented as adjusted odds ratios, with their 95% confidence interval.
*At least one prescription in 2008.claims data or on data on drugs dispensed over the
counter. Although they do not capture the over-the-
counter drug consumption or perfectly document adher-
ence to prescribed drug regimens, these prescription
data reflect the actual practice of French and Italian GPs
[23]. Although we selected antibiotics typically indicated
for respiratory tract infections, their prescription may
have also been for reasons other than asthma exacerba-
tion. We were unable to assess severity factors not readily
available (such as socioeconomic factors or spirometry) or
unreliable (such as smoking status) [24]. Because the de-
rived HEDIS criteria are partly based on drug prescrip-
tions to identify patients with persistent asthma, we may
have underestimated the proportion of asthmatic patients
in the GPs’ lists and the frequency of non-asthma-specifics (at least one prescription in 2008) according to
ressant prescriptions, after adjusting for asthma control
t least
= 6965)
Model 2 Prescription of at least one
anxiolytic/hypnotic in 2008 (n = 6965)
5.00 (3.45-5.26)
1.92 (1.33-2.76)
3.31 (2.33-4.72)
1.81 (1.53-2.14)
0.98 (0.81-1.19)
9.56 (7.69-11.89)
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prescription of at least one box of drug rather than the de-
fined daily dose because the aim of the study was primar-
ily to measure the frequency of prescription of antibiotics
and anxiolytics/hypnotics.
Antibiotic prescription
When presented with an asthma exacerbation, GPs are
likely to overestimate the risk of bacterial infection and
prescribe antibiotics [26,27]. This trend is associated
with the underuse of inhaled corticosteroids, probably
because of a misunderstanding of the immunosuppres-
sive effect of corticosteroids [28]. However, antibiotics
are frequently not useful in asthma exacerbations (for
those caused by viral infections, for example), unless
they are of bacterial origin or are associated with bacter-
ial acute sinusitis in children [1,29]. A computed tomog-
raphy scan is recommended for confirmation when
sinusitis is suspected in adult patients [1]. However, be-
cause the clinical features of sinusitis lack diagnostic
precision [30,31], GPs can face delays in getting access
to a computed tomography scan for their patients and
may prescribe antibiotics as a precautionary measure
[32]. Independently, evidence is lacking on the actual
value of the use of antibiotics, such as macrolide treat-
ment for at least 4 weeks, in the treatment of chronic
asthma [33]. The over-prescription of antibiotics to asth-
matic patients may cause adverse events, increase costs,
and contribute to the development of antibiotic resist-
ance in microbes [17]. Interestingly, antibiotic use in the
first year of life is a risk factor for asthma [34].
France and Italy belong to the group of European
countries with a high level of antibiotic consumption
(17–24 daily doses per day per 1000 inhabitants); France
is currently ranked second and Italy third, behind
Greece [35]. The small difference that we observed in
the numbers of antibiotic prescriptions between France
and Italy may be because such prescriptions are specific
for respiratory tract infections. Our results confirm that
women are prescribed more antibiotics than men
[36,37], which may be owing to poorer control of their
asthma, among possible reasons [3].
Anxiolytic and hypnotic prescriptions
Our estimation of the frequency of prescription of anxio-
lytics or hypnotics in French asthmatic patients (17.8 %) is
consistent with observations from the available dispensing
data (25.6% for anxiolytics and 13.0% for hypnotics) [26].
In Italy, we observed less frequent prescription of drugs in
this category (6.9%) compared with France. A possible ex-
planation for this finding is that patients must pay for all
benzodiazepine prescriptions [38]. Thus, a GP may prefer-
entially prescribe other reimbursable drugs. The high
prevalence of anxiety disorders and insomnia in France,especially in older people, may explain the high numbers
of prescriptions for anxiolytics and hypnotics [39]. More
specifically, these prescriptions may be related to poor
asthma control [3,40-42]. This relationship could be inter-
preted in two ways: asthma exacerbation could induce
anxiety [43] or psychiatric disorders could be risk factors
for asthma exacerbations [44].
There are guidelines that promote the provision of
psychological support to asthmatic patients and that rec-
ommend the limited prescription of psychotropic drugs
[31]. The long-term use of anxiolytics and hypnotics
should be avoided because of their addictive effect [45],
and their use should be avoided during asthma exacer-
bations because of their respiratory depressant effects,
which are potentially lethal [44]. Although cognitive-
behavioural therapies focussed on worry proneness and
the overvaluation of worry and uncertainty may be as ef-
fective as drug treatment and may be more durable for
treating anxiety disorders [46], these results remain to
be confirmed in asthmatic patients [47].
In Europe and North America, women are generally
prescribed twice as many psychotropic drugs as men
[48]. Psychiatric disorders and complaints are indeed
more common in women than in men [49]. Women
are also exposed to specific situations such as preg-
nancy, which can both worsen asthma and generate
anxiety [26,50]. In addition, women have fewer oppor-
tunities than men to control symptoms of anxiety
through social activities outside the home, including
the use of alcohol [51-53].
Implications for research, policy and practice
The high prevalence of antibiotic prescription in asthmatic
patients suggests a likely antibiotic over-prescription in
France and Italy. While anxiety is frequent in asthmatic
patients, the prescription of anxiolytics and hypnotics
should be avoided and the use of non-pharmacological in-
terventions should be considered in these patients. Apart
from international guidelines, there is only one French
guideline from 2004 on long-term asthma management.
The French guideline does not mention the prescription
of antibiotics and anxiolytics/hypnotics, and there are no
specific Italian recommendations on asthma management.
Conclusions
While it is known that many asthmatic patients do not
take specific controllers, the prescription of non-asthma-
specific drugs is common, especially in women. Asthmatic
patients often have additional health and life concerns.
GPs should use safe interventions and take a biopsychoso-
cial perspective. The prescription of antibiotics and anxio-
lytics/hypnotics to asthmatic patients should follow the
same rules that apply to their prescription in non-
asthmatic patients. Asthma guidelines should address this
Darmon et al. BMC Family Practice  (2015) 16:14 Page 7 of 8issue and refer to other guidelines covering the prescrip-
tion of these drugs. Alternative non-pharmacological in-
terventions should be considered.
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